A new mission for an old anti-cancer drug:harnessing hepatocyte-specific metabolic pathways against liver tumors
作者机构:Department of Medical OncologyCancer CenterWest China HospitalSichuan University610041 ChengduChina Cancer Biology ProgramUniversity of Hawaii Cancer CenterHonolulu 96813 HawaiiUSA Institute of PathologyUniversity of RegensburgRegensburg 93053Germany
出 版 物:《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗(英文))
年 卷 期:2023年第8卷第7期
页 面:3195-3197页
核心收录:
学科分类:1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学]
主 题:hepatocyte al. drug
摘 要:In a recent study published in Nature Cancer,Shi et *** the identification of the small molecule YC-1 as the selective drug against primary liver tumor cells due to the specific expression of sulfotransferase family 1A member 1(SULT1A1)in hepatocytelineage cells.1 This study offered new insights into repurposing an old anti-cancer drug via harnessing hepatocyte-specific metabolic enzymes to treat primary liver tumors.